Medtronic, a global leader in healthcare technology, today announced the first cases successfully using the Concerto Versa coil. It is indicated for arterial and venous embolization in the peripheral vasculature, helping to control bleeding or treat vascular disease. The first procedures using the Concerto Versa coil were performed by Dr. Rahul Patel, interventional radiologist, The Mount Sinai Hospital, in New York and Dr. Gloria Salazar, interventional radiologist, UNC Hospitals, Chapel Hill.

Specifically designed for large vessels, the Concerto Versa coil is a large volume coil compatible with many catheters while still maintaining optimal control. The Concerto Versa coil delivers more for peripheral embolization — more compatibility, more volume, and more control — while maintaining the small coil capabilities our Concerto™ helix and 3D coils are well known for.

“The ability to reposition the coil easily adds a level of control that’s very helpful,” said Dr. Patel. Added Dr. Salazar, “Whenever you’re dealing with tortuous anatomy, dual catheter compatibility becomes critical. If you can’t reach the target, you can’t treat it. Once you are in position, you need stability — that’s where smooth & controlled deployment really matters.”

Concerto Versa coil product features include: 

• Built with unparalleled catheter compatibility to let physicians address complex anatomies without sacrificing speed or precision.¹
  • Each coil has the flexibility to be used with both a diagnostic  catheter or microcatheter.
  • More efficient procedure time with 34% shorter catheterization time and 35% less radiation exposure during catheterization. ^†,1
• Designed with thick diameters and longer lengths to reduce the number of coils needed per procedure.^‡,1
  • Multi-sphere shape (3-14mm): designed to position and pack.
  • Sphere shape (16-32mm): designed to frame or fill.
  • 50% less inventory needed per diameter. ^§,1
• Combines high-volume capacity with small-coil control throughout procedures.
  • Softness makes it trackable through the most tortuous anatomy.¹
  • Detachment system has 99.7% reliability.¹
  • Fibers increase thrombogenicity compared to bare metal coils.²

“The Concerto Versa coil simplifies physician workflow by combining the benefits of a large volume coil with the ability to deliver through both microcatheters and diagnostic catheters. Embolization is an exciting market for Medtronic,  and we are investing to play a leadership role in driving new innovations for this therapy in the coming years,” said David Moeller, SVP and president of Peripheral Vascular Health, which is part of the Cardiovascular Portfolio at Medtronic.

The Concerto Versa coil has U.S. Food and Drug Administration clearance and is currently available in the United States. 

Footnotes:​
​TM* Third-party brands are trademarks of their respective owners.​
† Compared to other microcatheter compatible coils when a 4F diagnostic catheter (ID <=0.042") can be used to reach the embolization target. ​
‡ Compared to any other microcatheter compatible coil commercially available​
§ Compared to AZUR CX 35 and Interlock-35 for equivalent treatment options.​

References:​

1. Data on file at Medtronic D01346573_A Design characterization report Concerto Versa 2.0. Bench and animal testing may not be indicative of clinical performance.​
2. Girdhar G, Read M, Sohn J, Shah C, Shrivastava S. In-vitro thrombogenicity assessment of polymer filament modified and native platinum embolic coils. J Neurol Sci. April 15, 2014;339(1-2):97-101.​
3. Data on file at Medtronic D01448665_A Design characterization report Concerto Versa Coil Volume and Shelf Inventory Report.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Dr. Patel and Dr. Salazar are paid consultants for Medtronic.

Contacts:
Erin Burns
Public Relations
+1-612-827-8952

Ingrid Goldberg
Investor Relations
+1-763-505-2696